Crius Life Sciences Profile
Key Indicators
- Authorised Capital ₹ 5.00 Cr
as on 16-11-2024
- Paid Up Capital ₹ 5.00 Cr
as on 16-11-2024
- Company Age 8 Year, 10 Months
- Last Filing with ROC 31 Mar 2023
- Open Charges ₹ 47.10 Cr
as on 16-11-2024
- Revenue -4.16%
(FY 2023)
- Profit -54.13%
(FY 2023)
- Ebitda -36.91%
(FY 2023)
- Net Worth 21.97%
(FY 2023)
- Total Assets 23.06%
(FY 2023)
About Crius Life Sciences
The Company is engaged in the Healthcare Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 5.00 Cr and a paid-up capital of Rs 5.00 Cr.
The company currently has active open charges totaling ₹47.10 Cr.
Chinni Subbarao, Dalip Singh, and Birendra Chalaune serve as directors at the Company.
- CIN/LLPIN
U24232HP2016PTC001137
- Company No.
001137
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
02 Feb 2016
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Himachal Pradesh
Industry
Company Details
- Location
Solan, Himachal Pradesh, India
- Telephone
- Email Address
- Website
- Social Media-
Who are the key members and board of directors at Crius Life Sciences?
Board Members(3)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Chinni Subbarao  | Director | 02-Feb-2016 | Current |
| Dalip Singh | Director | 04-Mar-2022 | Current |
| Birendra Chalaune | Director | 28-Mar-2017 | Current |
Financial Performance of Crius Life Sciences.
Crius Life Sciences Private Limited, for the financial year ended 2023, experienced Minor drop in revenue, with a 4.16% decrease. The company also saw a substantial fall in profitability, with a 54.13% decrease in profit. The company's net worth Soared by an impressive increase of 21.97%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Crius Life Sciences?
In 2023, Crius Life Sciences had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
- Crius Health Private LimitedActive 3 years 2 months
Chinni Subbarao and Birendra Chalaune are mutual person
- Welzo Research & Development Private LimitedActive 2 years 19 days
Chinni Subbarao and Birendra Chalaune are mutual person
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Others Creation Date: 28 Aug 2024 | ₹7.16 M | Open |
Others Creation Date: 10 May 2024 | ₹2.80 Cr | Open |
Others Creation Date: 10 May 2024 | ₹5.75 Cr | Open |
How Many Employees Work at Crius Life Sciences?
Crius Life Sciences has a workforce of 245 employees as of Oct 06, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Crius Life Sciences, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Crius Life Sciences's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
